Stan Druckenmiller’s 10 Biggest Holdings

Stan Druckenmiller is widely regarded as one of the most successful macro investors in modern financial history. He’s known for his unparalleled track record and atypical investment strategy. Druckenmiller began his career in finance at Pittsburgh National Bank in 1977. From there, he rose rapidly through the ranks to head the bank’s equity research group by 1978. In 1981, he went his own way, founding Duquesne Capital Management.

This firm grew to manage over $12 billion in assets by the time he closed it in 2010, blaming the high emotional toll of managing large amounts. He famously orchestrated the legendary short on the British pound in 1992, known as “Black Wednesday,” and generated over $1 billion in profits for George Soros’ Quantum Fund. Druckenmiller maintained an average annual return of ~30% during his tenure, without a single year of losses. That said, he did get burned when he shorted internet stocks in the early 2000s. They kept rising, but his intuition ended up being correct when the bubble burst later on.

Druckenmiller now runs the Duquesne Family Office and invests his own money. His investment vehicle’s name may have changed, but the execution has not. It gained 9.07% in Q3 2025, and the portfolio has $3.93 billion in assets under management with 62 holdings. Druckenmiller is a big believer in pharmaceuticals, technology and emerging markets.

#10 Amazon.com, Inc. (AMZN)

Amazon was a new addition to Druckenmiller’s portfolio for the third quarter of 2025 (the most recent data available). He bought 437,000 shares with a net value of $95.97 million (2.44% of his overall holdings).

Amazon is likely both an e-commerce and AI play for the fund manager. The stock was up 3.75% in the last year.

#9 iShares MSCI Emerging Markets ETF (EEM)

This emerging markets fund was Druckenmiller’s largest new position for the third quarter of 2025. Duquesne sold some domestic stock positions while making this emerging markets play. The ETF is up 34.72% over the last year.

Duquesne bought 1.9 million shares valued at $101.46 million. That accounts for 2.8% of the portfolio.

#8 DocuSign, Inc. (DOCU)

Druckenmiller greatly increased his holdings (by 30.65%) of DocuSign, the electronic signature software company. He holds 1.69 million shares valued at $121.54 million (3.09% of the overall holdings).

The fund manager likely sees the company as undervalued. The stock struggled in 2025, down 28.68% in one year.

#7 MercadoLibre Inc. (MELI)

MercadoLibre is Latin America’s dominant e-commerce and fintech player, running online marketplaces and payment systems across the region. The company has been posting eye-catching revenue and earnings growth. MELI rose 17.64% in the last year.

Druckenmiller’s increased stake (by 8.6%) in MercadoLibre shows his interest in companies with strong moats and ties to growth in emerging markets. MercadoLibre’s solid staying power seems to be what he likes.

Druckenmiller owns 58,000 shares valued at $136.35 million (3.47% of the portfolio).

#6 Coupang Inc. (CPNG)

Coupang is South Korea’s top e-commerce platform, known for lightning-fast delivery and a steady retail experience for millions of shoppers. The company has poured money into logistics. Continued growth in online shopping and deep market penetration make it relevant for investors watching Asian tech and consumer behavior.

Druckenmiller increased his Coupang stake by 12.85%. He now owns 4.63 million shares, valued at $149.19 million. The holding (3.79% of his portfolio) matches his approach of backing dominant e-commerce players in key global markets that still have room to expand long-term.

#5 Woodward Inc. (WWD)

Woodward Inc. sells control solutions for aerospace and industrial markets. It makes components needed for engine and energy system efficiency. Rising demand for advanced control systems in sustainable energy and aviation makes Woodward highly relevant today.

Druckenmiller’s interest in Woodward lines up with his view that industrial innovation and infrastructure upgrades are enduring trends. But he decreased his holdings by 25.43% in Q3. He now holds 633,000 shares valued at $159.97 million (4.07% of the portfolio).

#4 Taiwan Semiconductor Manufacturing Co. (TSM)

TSMC is the undisputed global leader in advanced semiconductor manufacturing, making chips for virtually every major tech company. The company’s chip-on-wafer-on-substrate technology and huge planned capacity expansions place it squarely at the heart of the AI and cloud-computing boom.

Druckenmiller seems to have strong conviction in the long-term prospects of semiconductor manufacturing, especially as AI and data infrastructure spending take off. TSMC’s commanding industry position and scalable business model make it a perfect choice for capturing growth in next-generation computing.

Duquesne holds 765,000 shares, valued at $213.68 million. That constitutes 5.44% of the overall holdings. The stock was up 55.44% in one year.

#3 Teva Pharmaceutical Industries (TEVA)

Teva is one of the world’s biggest generic drug makers, also developing specialty and branded medicines. Its global footprint and know-how in affordable medicines make it essential for healthcare systems looking for cost-effective treatments. Teva has recently benefited from tariff relief on European pharmaceutical products thanks to new U.S.-EU trade deals and keeps diversifying with focus on both generics and new drugs for common conditions like arthritis and migraines.

Druckenmiller built his Teva stake as the company rebounded operationally with better revenue trends and helpful trade developments like tariff relief. His investment likely means he sees Teva as undervalued with turnaround potential, plus belief that ongoing restructuring and growth in high-margin innovative drugs could deliver major upside.

Duquesne bought 625,000 more shares in Q3. The holdings (16.59 million shares) represent 8.53% of the overall portfolio. The stock was up 45.65% in the last year.

#2 Insmed Inc. (INSM)

Insmed Inc. is a biopharmaceutical company that makes therapies for rare and serious diseases, particularly in lung health and infectious disease. Its pipeline has treatments for tough-to-treat lung conditions.

Druckenmiller boosted his Insmed stake considerably, increasing his position by 7.54%. He now owns 2.24 million shares valued at $349 million. That’s 8.8% of the Duquesne portfolio. He seems to have a bullish view on biotech and rare disease treatments. His conviction likely traces back to Insmed’s clinical progress and the chance for its therapies to grab market share in rare diseases.

#1 Natera Inc (NTRA)

Natera Inc. specializes in genetic testing services, including non-invasive prenatal testing, cancer diagnostics, and organ health monitoring. The company leads in precision medicine. It uses advanced genomics to improve early disease detection. There is growing demand for personalized healthcare and the accelerating adoption of genetic testing as standard medical practice.

Druckenmiller holds a massive position in Natera (3.21 million shares with a market value of $517.44 million). This represents 13.16% of the portfolio and he increased his holdings by 4.19%. He presumably likes the company’s ability to benefit from major trends in precision medicine and genomics. The stock was up 40.38% in the last year.

The image featured at the top of this post is ©Neilson Barnard / Getty Images Entertainment via Getty Images.